Here’s our roundup of interesting topics recently in the news:
There are almost 2,000 known mutations of the CFTR gene which lead to varying degrees of Cystic fibrosis disease symptoms. The CFTR2 Project, launched in 2010, took a stab at categorizing these mutations and resulted in 276 annotated variants. A number of new projects are in the works to continue classifying the remaining mutations.
The first uterine transplant procedure done earlier this year in the US initially drew a lot of excitement. However, the patient developed complications and the transplant unfortunately had to be removed. Doctors plan to take extra precautions to prevent similar complications in future patients as there is still interest in completing the experimental procedure several more times. While some experts are excited at the opportunity of offering this procedure, others question it, fearing the risks that accompany a major surgery. Read both sides of the argument, here.
CRISPR has been all the rage in the scientific world for what seems like eons. What’s up next for the gene-editing technique? Its first human trial in the US. An advisory committee for the US National Institutes of Health unanimously approved a trial that will use CRISPR to edit a type of human immune cell in order to engineer it to better fight cancer.
In April, 2003, the Human Genome was declared complete, but in actuality, it was “as complete as it can be.” Read an argument as to why we should truly finish the project.
Where the field of genetic counseling was, is, and is going. And why it’s all about you, the patient.
And finally, zombie genes: need we say more?
Thanks for reading!